Clinical Trial Update: Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the impact of combining endocrine therapy with abemaciclib on host and tumor immune cell repertoire in advanced ER+/HER2- breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Endocrine therapy

Snippet

Sponsor: Duke University | Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Status: COMPLETED